Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3083] to Fibrinogen beta chain (HRP)
- Suitable for: WB
- Reacts with: Mouse, Human
- Conjugation: HRP
Product nameAnti-Fibrinogen beta chain antibody [EPR3083] (HRP)
See all Fibrinogen beta chain primary antibodies
DescriptionRabbit monoclonal [EPR3083] to Fibrinogen beta chain (HRP)
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Human
Predicted to work with: Rat
within Human Fibrinogen beta chain aa 400 to the C-terminus. The exact sequence is proprietary.
Database link: P02675
- WB: Human Platelet, Mouse Platelet, Human Plasma and Mouse Plasma lysates.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: 30% Glycerol, 1% BSA, PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab212218 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/5000. Detects a band of approximately 56 kDa (predicted molecular weight: 56 kDa).|
FunctionFibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.
Involvement in diseaseDefects in FGB are a cause of congenital afibrinogenemia (CAFBN) [MIM:202400]. This rare autosomal recessive disorder is characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Note=Patients with congenital fibrinogen abnormalities can manifest different clinical pictures. Some cases are clinically silent, some show a tendency toward bleeding and some show a predisposition for thrombosis with or without bleeding.
Sequence similaritiesContains 1 fibrinogen C-terminal domain.
DomainA long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure.
modificationsConversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
- Information by UniProt
- Beta fibrinogen antibody
- Epididymis Secretory Sperm Binding Protein Li 78p antibody
- FGB antibody
All lanes : Anti-Fibrinogen beta chain antibody [EPR3083] (HRP) (ab212218) at 1/5000 dilution
Lane 1 : Human Platelet lysate
Lane 2 : Mouse Platelet lysate
Lane 3 : Human Plasma lysate
Lane 4 : Mouse Plasma lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 56 kDa
Observed band size: 56 kDa
Exposure time: 3 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab212218 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab212218 has not yet been referenced specifically in any publications.